FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,010 letters match. Newest first.

  1. Maui Seafood LLC

    Maui Seafood LLC's Las Vegas RTE tuna and salmon plant had Listeria monocytogenes (a harmful bacterium) and seafood safety plan sanitation violations.

    High risk
  2. Cohance Lifesciences Limited

    Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.

    High risk
  3. HTO Nevada, Inc. dba Kirkman

    HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.

    High risk
  4. Flextronics America LLC

    FDA warns Flextronics America, contract maker of FreeStyle Libre 3 glucose sensors in Austin, TX, over an unvalidated assembly step and weak corrective actions.

    High risk
  5. Abbott Diabetes Care, Inc.

    FDA warns Abbott Diabetes Care that FreeStyle Libre 3 glucose monitors lacked design transfer and finished-device accuracy release testing.

    High risk
  6. CC Pollen Company

    FDA warns CC Pollen Company of Glendale, Arizona, that its bee pollen and royal jelly supplements are adulterated and misbranded.

    High risk
  7. Unomedical Device S.A. de C.V.

    FDA warns Unomedical over insulin infusion sets with unvalidated leak tests and unreported serious injuries.

    High risk
  8. Eniva USA, Inc.

    FDA warns Eniva USA over manufacturing quality failures for Immune Support and Ashwagandha Gummies.

    Medium
  9. Carolina Seafood Inc.

    FDA warned Carolina Seafood that its ready-to-eat crab and shrimp dips had inadequate seafood hazard-control plans.

    High risk
  10. Fulijaya Manufacturing SDN. BHD.

    Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.

    High risk
  11. Meridian Bioscience, Inc

    FDA warns Meridian Bioscience's Magellan Diagnostics over quality system failures and unreported problems with its blood lead test kits.

    High risk
  12. MAST Biosurgery USA, Inc.

    MAST Biosurgery USA never ran promised endotoxin tests on its SurgiWrap FROST surgical mesh and failed to report patient injuries, FDA says.

    High risk
  13. Integrity Partners Group

    FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.

    High risk
  14. Winder Laboratories, LLC

    FDA warns Winder Laboratories of adulterated prescription drugs due to cleaning and facility failures.

    High risk
  15. LXR Biotech, LLC

    FDA warns LXR Biotech over CGMP (manufacturing quality rules) failures for Eternal Energy supplements, making them adulterated (legally unfit as made).

    Medium
  16. Chemspec Chemicals Private Limited

    FDA warns Indian API maker Chemspec Chemicals over missing batch records and data integrity failures.

    High risk
  17. ASP Global, LLC. dba Anatomy Supply Partners, LLC.

    FDA cites ASP Global for quality-system, reporting, and unapproved-change violations involving Safe-T-Fill blood collection devices.

    High risk
  18. Pan-African Food Distributors Inc./East Africa Boutique LLC

    FDA found widespread rodent and insect infestation in Pan-African Food Distributors’ warehouse holding dietary supplements, foods and cosmetics.

    High risk
  19. Middle East/Soli's Baking Company, Inc. dba Middle East Baking Co.

    FDA found live insects and rodent droppings throughout Middle East Baking's pita and bagel plant in Burlingame, California.

    High risk
  20. Absolutely Natural

    FDA warned Absolutely Natural of Melbourne, Florida, over nonprescription drug manufacturing violations, including weak contamination investigations and component testing.

    High risk
  21. Tower Laboratories Ltd.

    FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

    High risk
  22. LiquidCapsule Manufacturing, LLC

    LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.

    High risk
  23. Unipack LLC

    FDA says Unipack LLC released suppositories without adequate out-of-specification investigations, complete lab records, and required USP testing.

    High risk
  24. Private Label Skin Care, Inc.

    FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.

    High risk
  25. Guangdong Renhe Guozhuang Biotechnology Co., Ltd.

    FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.

    High risk
  26. Medinatura New Mexico, Inc.

    FDA cited Medinatura New Mexico for drug manufacturing rule violations, including weak component testing and cleaning.

    High risk
  27. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk
  28. Darmerica, LLC

    FDA warns Darmerica over manufacturing-quality violations and mislabeled drug ingredients, including retatrutide.

    High risk
  29. King Farm

    King Farm's horse feed held fumonisin up to 36.1 ppm; FDA ties it to at least 30 horse deaths.

    High risk
  30. Sklar Personal Care Inc.

    Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.

    High risk
  31. 3D Imaging Drug Design and Development LLC

    FDA warns 3D Imaging of CGMP failures in sterile PET drug manufacturing and outdated drug listings.

    High risk
  32. Microvascular Tissue, Inc.

    FDA says Microvascular Tissue's mVASC wound product is an unapproved drug and unlicensed biologic, made without validated processes.

    High risk
  33. Harbor Marine Product Inc.

    FDA found Listeria bacteria on raw ready-to-eat fish contact surfaces and serious seafood HACCP and importer verification failures at Harbor Marine Product.

    High risk
  34. Catalent Indiana, LLC

    Catalent Indiana's Bloomington plant released sterile vials contaminated with mammalian hair and failed to investigate, FDA says.

    High risk
  35. Seaway Pharma Inc.

    FDA cited Seaway Pharma for manufacturing-quality rule violations in OTC oral liquid drugs, including release and component-testing failures.

    High risk
  36. CDL Services, Inc. DBA Technichem

    FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.

    High risk
  37. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk
  38. Envoy Medical Inc.

    Envoy Medical in Saint Paul, MN was cited for quality system failures in making its Esteem II Implantable Hearing System, including slow complaint investigations and missed cleanroom contamination risks.

    High risk
  39. Delucas Bakery Corp

    FDA warns Delucas Bakery Corp over unsanitary conditions, missing food safety plan, and undeclared allergens in ready-to-eat rolls and buns.

    High risk
  40. Rhyz Analytical Labs

    FDA warned Rhyz Analytical Labs, a contract drug testing lab, that inadequate microbial failure investigations and quality oversight made tested drugs adulterated.

    High risk
  41. PQ Pharmacy, LLC

    FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.

    High risk
  42. Handelnine Global, LLC dba Navafresh

    Navafresh sells unapproved Ayurvedic drugs online, and its Rheumacare Capsules contain about 7,000 times the lead level of concern.

    High risk
  43. Wells Pharma of Houston, LLC

    FDA warns Wells Pharma of Houston over sterile compounded drugs made under insanitary conditions.

    High risk
  44. Owen Biosciences, Inc.

    Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.

    High risk
  45. Hong Qiangxing Shenzhen Electronics Limited

    FDA warned Hong Qiangxing Shenzhen Electronics after an inspection found quality-system violations in TENS, muscle stimulator, and blood pressure monitor manufacturing.

    Medium
  46. Cdymax India Pharma Private Limited

    FDA warned Cdymax (India) Pharma that its Bangalore API plant had inadequate out-of-specification investigations and unvalidated test methods, making its APIs adulterated.

    High risk
  47. Seema International

    FDA warns Seema International over unclean API equipment, missing stability data, and quality-unit failures after inspection; APIs adulterated.

    High risk
  48. Siddha Flower Essences, LLC., dba Siddha Remedies

    FDA cites Siddha Remedies, a maker of children's homeopathic drugs, for untested water and botanicals and microbial contamination.

    High risk
  49. World Perfumes Inc.

    World Perfumes failed to test drug ingredients for toxic contaminants and had inadequate water, FDA says.

    High risk
  50. DermaRite Industries, LLC

    DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.

    High risk